Arbutus Biopharma CorpABUSEarnings & Financial Report

Nasdaq · pharmaceutical industry

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

NextMar 31, 2026

Revenue

$529.0K

Gross Profit

N/A

Operating Profit

$-8.7M

Net Profit

$-7.7M

Gross Margin

N/A

Operating Margin

-1636.9%

Net Margin

-1463.5%

YoY Growth

-60.5%

EPS

$-0.04

Financial Flow

Arbutus Biopharma Corp Q3 2025 Financial Summary

Arbutus Biopharma Corp reported revenue of $529.0K for Q3 2025, with a net profit of $-7.7M (-1463.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$529.0K
Net Profit	$-7.7M
Gross Margin	N/A
Operating Margin	-1636.9%
Report Period	Q3 2025

Arbutus Biopharma Corp Annual Revenue by Year

Arbutus Biopharma Corp annual revenue history includes year-by-year totals (for example, 2024 revenue was $6.2M).

Year	Annual Revenue
2024	$6.2M
2023	$18.1M
2022	$39.0M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$2.1M	$1.5M	$1.7M	$1.3M	$1.6M	$1.8M	$10.7M	$529000
YoY Growth	-65.7%	-77.1%	-62.9%	-71.3%	-26.6%	15.1%	522.2%	-60.5%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$144.4M	$150.3M	$160.0M	$140.4M	$131.7M	$117.0M	$103.3M	$97.7M
Liabilities	$38.4M	$35.7M	$37.6M	$33.6M	$34.3M	$37.9M	$20.3M	$20.3M
Equity	$106.0M	$114.6M	$122.5M	$106.9M	$97.4M	$79.2M	$83.0M	$77.4M